

Syngene

Putting Science to Work


Accelerating Biologics Discovery

Your Global Partner in Biologics Innovation




With over 30 years of experience, Syngene is a trusted global CRO/CDMO, delivering end-to-end solutions across discovery, development, and manufacturing for biologics. Our integrated platform positions us as a true 'one-stop-shop' for solving complex scientific challenges. Over 400 customers globally rely on our scientific excellence, reflected in more than 400 client-assigned patents recognizing our contributions to their breakthroughs.

Partner with Syngene - where innovation meets excellence.




Having a single partner with a broad suite of capabilities as opposed to multiple specialty partners, means being able to manage projects centrally, unhindered by logistical/shipping delays or dependencies on third-party deliverables. This enables timely completion of projects, efficiency, and cost savings.


Leading CRO/CDMO Syngene offers end-to-end Biologics Development and Manufacturing solutions for mammalian and microbial systems across modalities and therapeutic areas. We also offer Sterile Fill-Finish and Viral Testing services, making us a one-stop solution for all Biologics requirements – Target to Therapy!




Antibody Discovery: Leveraging multiple platforms for biotherapeutic and tool antibodies




We can generate antibodies in ~12 weeks using RIMMS approach and ~21 weeks using standard immunization approach




We offer a rich suite of antibody engineering capabilities



We have breadth of capabilities to support your ADC research and development end to end



Unlock breakthroughs with Syngene's genomic and translational sciences



Syngene offers a comprehensive suite of services across cloning, next-generation sequencing (NGS), mRNA synthesis, antibody repertoire sequencing, therapeutic antibody discovery, and biomarker identification.


Our expertise spans fast-turnaround gene cloning, custom vector design, full-spectrum NGS, high-quality mRNA production with LNP formulation, and advanced immune repertoire analysis. Leveraging cutting-edge phage and yeast display platforms, we rapidly discover and optimize therapeutic and diagnostic antibodies against a wide range of targets.

Our biomarker discovery capabilities further empower precision medicine initiatives by delivering clinically actionable insights.


Partner with Syngene to translate genomic data into meaningful breakthroughs.



NGS & Sanger sequencing services




Cell Engineering – One stop solution for reagent cell line generation



- Syngene cell engineering team offers one stop solution for all reagent cell lines which can be used for various aspects of pharmacological and small molecule drug discovery
- Our expertise having very ~ 22 years of experience in cell line engineering equipped us to provide quicker and scientific and strategic solutions to generate knock out in any given cell line. We successfully tested our optimised protocol in ~80 cell lines
- Our expertise in over expression lines enables us to generate cells with differential receptor densities which serves as excellent tools for ADC and CDCC assays
- Lentiviral based design of reporter vectors lead us to generate reporter cell lines for various signalling pathways with high sensitivity as low as nM range detection with longer stability up to ~ 20 passages
- We are well equipped with designing new vectors according to the client needs from the scratch. This enables stable expression of target genes over ~ 20 passages OR 40 generations
- Our landing pad technology developed at safe harbour site provides us to generate monoclonal cell lines as quick as us to generate monoclonal equivalent cell lines as quick as ~ 6 weeks
- In addition, we offer transient transfection studies, siRNA, shRNA and viral vector designing and generation

Work flow for knock out and knock in generations and QC



Accelerate your biologics development & bio manufacturing with our expertise



Cell Line Development

- Proprietary CHO line
- Transposon transfection
- 9 weeks DNA to RCB
- > 95% clonal stability



Analytics

- Product characterization
- Bioassays
- Mass Spec, NMR, AUC
- Release & stability assays



Process Development

- High throughput
- USP | DSP
- Process optimization
- Process characterization



Clinical Batch Manufacturing

- 50L - 2K L SUBs
- 40K L capacity
- Formulation | F&F
- Viral clearance

Our competence - your advantage

Trust

- 25+ INDs enabled
- Top 15 global biopharma clients
- 140+ successful projects



Speed & Reliability

- 10 months from CLD to clinic
- Real time data sharing
- Start within 4 weeks from signing

Success by Design

- 7 - 12 g/L titers achieved
- Proven process scalability
- End-to-end in-house service




Value

- Uncompromised quality
- Royalty-free
- Flexible payment structure

Drug substance and drug product manufacturing services

- Dual manufacturing site in India and in the US: We ensure seamless supply continuity between sites in India and North America
- Total single use bioreactor (SUB) capacity of 50,000 liters, with individual SUBs ranging from 50 to 4,000 liters
- Our India manufacturing site is approved by US FDA, EMA, ANVISA and PMDA and has produced more than 250 GMP batches
- Drug product services: Vials | PFS | Cartridges
- Integrated capacity of 1 million vials per day

Sequence to vial in 10 months



Notes

Syngene

Putting Science to Work

Scan the QR code
to learn more



About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's 6000+ scientists offer both skills and the capacity to deliver great science, robust data security, and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Baxter, and Bristol-Myers Squibb, as well as 2.2 million sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis, and Merck KGaA.

For more details, visit www.syngeneintl.com or write to us at bdc@syngeneintl.com

© 2026 Syngene International Limited, All Rights Reserved.

Stay Connected

